Open AccessOncogenic LINC00857 recruits TFAP2C to elevate FAT1 expression in gastric cancer
Author(s) -
Zhang Wenqing,
Ji Kaiyue,
Min Congcong,
Zhang Cuiping,
Yang Lin,
Zhang Qi,
Tian Zibin,
Zhang Mengyuan,
Wang Xinyu,
Li Xiaoyu
Publication year - 2023
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/cas.15394
Subject(s) - gene silencing , downregulation and upregulation , cadherin , carcinogenesis , transcription factor , cancer research , biology , epithelial–mesenchymal transition , cancer , gene , cell , genetics
FAT atypical cadherin 1 (FAT1) is a mutant gene frequently found in human cancers and mainly accumulates at the plasma membrane of cancer cells. Emerging evidence has implicated FAT1 in the progression of gastric cancer (GC). This study intended to identify a regulatory network related to FAT1 in GC development. Upregulated expression of FAT1 was confirmed in GC tissues, and silencing FAT1 was observed to result in suppression of GC cell oncogenic phenotypes. Mechanistic investigation results demonstrated that FAT1 upregulated AP‐1 expression by phosphorylating c‐JUN and c‐FOS, whereas LINC00857 elevated the expression of FAT1 by recruiting a transcription factor TFAP2C. Functional experiments further suggested that LINC00857 enhanced the malignant biological characteristics of GC cells through TFAP2C‐mediated promotion of FAT1. More importantly, LINC00857 silencing delayed the tumor growth and blocked epithelial–mesenchymal transition in tumor‐bearing mice, which was associated with downregulated expression of TFAP2C/FAT1. To conclude, LINC00857 plays an oncogenic role in GC through regulating the TFAP2C/FAT1/AP‐1 axis. Therefore, this study contributes to extended the understanding of gastric carcinogenesis and LINC00857 may serve as a therapeutic target for GC.